a Clinical Trial and was just randomized to get the study drug. They use the tyrosine kinase inhibitors for this particular cancer/cell surface marker (EGFR)in late stage disease and it provides progressive free disease for up to 3 years before it progresses. This study is testing it in early stage disease. The study is called the ALCHEMIST trial. Standard of care after resection and adjuvant therapy is observation. The two arms are observation or drug. Erlotinib is a first generation TKI. There is another now that does cross the blood brain barrier.
Please keep him in your prayers...thank you.